{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:18:59Z","timestamp":1785799139262,"version":"3.56.0"},"reference-count":55,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T00:00:00Z","timestamp":1724803200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Derm Venereol"],"abstract":"<jats:p>Skin toxicities caused by epidermal growth factor receptor tyrosine kinase inhibitors can affect patient quality of life and lead to treatment adjustments, including dose reduction or discontinuation. This retrospective study aimed to profile skin toxicities and their impact on treatment adjustments. A total of 288 non-small cell lung cancer patients treated with first-, second-, or third-generation epidermal growth factor receptor tyrosine kinase inhibitors were included. Skin toxicities, including papulopustular rash, xerosis, paronychia, and pruritus, were assessed based on medical records, and their severity was evaluated based on the required dermatological intervention. Papulopustular rash was the most common toxicity (74.3%), followed by pruritus (61.1%), xerosis (52.4%), and paronychia (39.6%). Papulopustular rash was more common in males and more severe in younger patients. Papulopustular rash was more prevalent in patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors, while paronychia was notably frequent for the second-generation epidermal growth factor receptor tyrosine kinase inhibitors. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors frequently caused multiple skin toxicities. Importantly, skin toxicities led to epidermal growth factor receptor tyrosine kinase inhibitor treatment adjustments in 26.7% of cases, with second-generation epidermal growth factor receptor tyrosine kinase inhibitors demonstrating higher adjustment rates. Papulopustular rash and paronychia were the main causes of treatment adjustments, with even mild paronychia being linked to treatment adjustments. Effective management of skin toxicities is essential for optimizing treatment outcomes in patients receiving epidermal growth factor receptor tyrosine kinase inhibitors.<\/jats:p>","DOI":"10.2340\/actadv.v104.40555","type":"journal-article","created":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T07:43:00Z","timestamp":1724830980000},"page":"adv40555","source":"Crossref","is-referenced-by-count":9,"title":["Skin Toxicities Induced by Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and their Influence on Treatment Adjustments in Lung Cancer Patients"],"prefix":"10.2340","volume":"104","author":[{"given":"Ji Su","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimin","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Min","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namkyu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Jin","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2024,8,28]]},"reference":[{"key":"72458","doi-asserted-by":"crossref","unstructured":"Sun W, Li J. Skin toxicities with epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients: a meta-analysis of randomized controlled trials. Cancer Invest 2019; 37: 253-264.","DOI":"10.1080\/07357907.2019.1634089"},{"key":"72459","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/07357907.2019.1634089","DOI":"10.1080\/07357907.2019.1634089"},{"key":"72460","doi-asserted-by":"crossref","unstructured":"Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425-1433.","DOI":"10.1093\/annonc\/mdi279"},{"key":"72461","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdi279","DOI":"10.1093\/annonc\/mdi279"},{"key":"72462","doi-asserted-by":"crossref","unstructured":"Li Y, Fu R, Jiang T, Duan D, Wu Y, Li C, et al. Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies. Front Oncol 2022; 12: 804212.","DOI":"10.3389\/fonc.2022.804212"},{"key":"72463","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3389\/fonc.2022.804212","DOI":"10.3389\/fonc.2022.804212"},{"key":"72464","doi-asserted-by":"crossref","unstructured":"Joly-Tonetti N, Ondet T, Monshouwer M, Stamatas GN. EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function. BMC Cancer 2021; 21: 5.","DOI":"10.1186\/s12885-020-07685-5"},{"key":"72465","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1186\/s12885-020-07685-5","DOI":"10.1186\/s12885-020-07685-5"},{"key":"72466","doi-asserted-by":"crossref","unstructured":"Annunziata MC, De Stefano A, Fabbrocini G, Leo S, Marchetti P, Romano MC, et al. Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer. Clin Drug Investig 2019; 39: 825-834.","DOI":"10.1007\/s40261-019-00811-7"},{"key":"72467","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40261-019-00811-7","DOI":"10.1007\/s40261-019-00811-7"},{"key":"72468","unstructured":"Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000; 10: 505-510."},{"key":"72469","unstructured":"Mitchell EP, Perez-Soler R, Van Cutsem E, Lacouture ME. Clinical presentation and pathophysiology of EGFRI dermatologic toxicities. Oncology (Williston Park, NY), 2007; 21: 4-9."},{"key":"72470","doi-asserted-by":"crossref","unstructured":"Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2016; 17: 367-377.","DOI":"10.1016\/S1470-2045(15)00551-3"},{"key":"72471","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S1470-2045(15)00551-3","DOI":"10.1016\/S1470-2045(15)00551-3"},{"key":"72472","doi-asserted-by":"crossref","unstructured":"Abourehab MAS, Alqahtani AM, Youssif BGM, Gouda AM. Globally approved EGFR inhibitors: insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism. Molecules (Basel, Switzerland), 2021; 26.","DOI":"10.3390\/molecules26216677"},{"key":"72473","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3390\/molecules26216677","DOI":"10.3390\/molecules26216677"},{"key":"72474","doi-asserted-by":"crossref","unstructured":"He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd\u2011generation EGFR\u2011TKI resistance in advanced non\u2011small cell lung cancer (Review). Int J Oncol 2021; 59: 90.","DOI":"10.3892\/ijo.2021.5270"},{"key":"72475","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.3892\/ijo.2021.5270","DOI":"10.3892\/ijo.2021.5270"},{"key":"72476","doi-asserted-by":"crossref","unstructured":"Westover D, Zugazagoitia J, Cho BC, Lovly CM, Paz-Ares L. Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors. Ann Oncol 2018; 29: i10-i19.","DOI":"10.1093\/annonc\/mdx703"},{"key":"72477","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1093\/annonc\/mdx703","DOI":"10.1093\/annonc\/mdx703"},{"key":"72478","doi-asserted-by":"crossref","unstructured":"Macdonald JB, Macdonald B, Golitz LE, LoRusso P, Sekulic A. Cutaneous adverse effects of targeted therapies, Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol 2015; 72: 203-218; quiz 219-220.","DOI":"10.1016\/j.jaad.2014.07.032"},{"key":"72479","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jaad.2014.07.032","DOI":"10.1016\/j.jaad.2014.07.032"},{"key":"72480","doi-asserted-by":"crossref","unstructured":"Chu CY, Choi J, Eaby-Sandy B, Langer CJ, Lacouture ME. Osimertinib: a novel dermatologic adverse event profile in patients with lung cancer. Oncologist 2018; 23: 891-899.","DOI":"10.1634\/theoncologist.2017-0582"},{"key":"72481","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0582","DOI":"10.1634\/theoncologist.2017-0582"},{"key":"72482","unstructured":"Institute NC. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Washington, DC: US Department of Health and Human Services, 2017."},{"key":"72483","doi-asserted-by":"crossref","unstructured":"Chu C-Y, Chen K-Y, Wen-Cheng Chang J, Wei Y-F, Lee C-H, Wang W-M. Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities. J Formos Med Assoc 2017; 116: 413-423.","DOI":"10.1016\/j.jfma.2017.03.001"},{"key":"72484","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.jfma.2017.03.001","DOI":"10.1016\/j.jfma.2017.03.001"},{"key":"72485","doi-asserted-by":"crossref","unstructured":"Zhao Y, Cheng B, Chen Z, Li J, Liang H, Chen Y, et al. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: a systematic review and network meta-analysis. Crit Rev Oncol Hematol 2021; 160: 103305.","DOI":"10.1016\/j.critrevonc.2021.103305"},{"key":"72486","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.critrevonc.2021.103305","DOI":"10.1016\/j.critrevonc.2021.103305"},{"key":"72487","doi-asserted-by":"crossref","unstructured":"Chan A, Tan EH. How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors? Supportive Care Cancer 2011; 19: 1667-1674.","DOI":"10.1007\/s00520-010-0999-2"},{"key":"72488","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s00520-010-0999-2","DOI":"10.1007\/s00520-010-0999-2"},{"key":"72489","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Moosmann N, Klein E, Katzer K. A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 2008; 17: 790-792.","DOI":"10.1111\/j.1600-0625.2008.00715.x"},{"key":"72490","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1600-0625.2008.00715.x","DOI":"10.1111\/j.1600-0625.2008.00715.x"},{"key":"72491","doi-asserted-by":"crossref","unstructured":"Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncol 2018; 14: 2531-2541.","DOI":"10.2217\/fon-2018-0187"},{"key":"72492","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/fon-2018-0187","DOI":"10.2217\/fon-2018-0187"},{"key":"72493","doi-asserted-by":"crossref","unstructured":"Le-Rademacher JG, Rowland K, Atherton PJ, Dakhil C, Sun Z, Tan A, et al. Androgen mediation - and antiandrogens mitigation - of the epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from a pilot randomized trial and small translational case series. Am J Hosp Palliat Care 2019; 36: 519-525.","DOI":"10.1177\/1049909118819820"},{"key":"72494","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1049909118819820","DOI":"10.1177\/1049909118819820"},{"key":"72495","doi-asserted-by":"crossref","unstructured":"Nakahara T, Moroi Y, Takayama K, Itoh E, Kido-Nakahara M, Nakanishi Y, et al. Changes in sebum levels and the development of acneiform rash in patients with non-small cell lung cancer after treatment with EGFR inhibitors. Onco Targets Ther 2015; 8: 259-263.","DOI":"10.2147\/OTT.S76860"},{"key":"72496","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/OTT.S76860","DOI":"10.2147\/OTT.S76860"},{"key":"72497","doi-asserted-by":"crossref","unstructured":"Reenstra WR, Yaar M, Gilchrest BA. Aging affects epidermal growth factor receptor phosphorylation and traffic kinetics. Exp Cell Res 1996; 227: 252-255.","DOI":"10.1006\/excr.1996.0274"},{"key":"72498","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1006\/excr.1996.0274","DOI":"10.1006\/excr.1996.0274"},{"key":"72499","doi-asserted-by":"crossref","unstructured":"Jatoi A, Green EM, Rowland KM, Jr., Sargent DJ, Alberts SR. Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 2009; 77: 120-123.","DOI":"10.1159\/000229751"},{"key":"72500","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1159\/000229751","DOI":"10.1159\/000229751"},{"key":"72501","doi-asserted-by":"crossref","unstructured":"Beech J, Germetaki T, Judge M, Paton N, Collins J, Garbutt A, et al. Management and grading of EGFR inhibitor-induced cutaneous toxicity. Future Oncology 2018; 14: 2531-2541.","DOI":"10.2217\/fon-2018-0187"},{"key":"72502","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2217\/fon-2018-0187","DOI":"10.2217\/fon-2018-0187"},{"key":"72503","doi-asserted-by":"crossref","unstructured":"Finlay MRV, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem, 2014; 57: 8249-8267.","DOI":"10.1021\/jm500973a"},{"key":"72504","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1021\/jm500973a","DOI":"10.1021\/jm500973a"},{"key":"72505","doi-asserted-by":"crossref","unstructured":"Russo A, Franchina T, Ricciardi GRR, Smiroldo V, Picciotto M, Zangh\u00ec M, et al. Third generation EGFR TKIs in EGFR-mutated NSCLC: where are we now and where are we going. Crit Rev Oncol Hematol 2017; 117: 38-47.","DOI":"10.1016\/j.critrevonc.2017.07.003"},{"key":"72506","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.07.003","DOI":"10.1016\/j.critrevonc.2017.07.003"},{"key":"72507","doi-asserted-by":"crossref","unstructured":"Shah DR, Shah RR, Morganroth J. Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy. Drug Safety 2013; 36: 413-426.","DOI":"10.1007\/s40264-013-0050-x"},{"key":"72508","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1007\/s40264-013-0050-x","DOI":"10.1007\/s40264-013-0050-x"},{"key":"72509","doi-asserted-by":"crossref","unstructured":"Bollinger MK, Agnew AS, Mascara GP. Osimertinib: a third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation. J Oncol Pharm Pract 2018; 24: 379-388.","DOI":"10.1177\/1078155217712401"},{"key":"72510","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1177\/1078155217712401","DOI":"10.1177\/1078155217712401"},{"key":"72511","doi-asserted-by":"crossref","unstructured":"Chen P, Chen F, Lei J, Zhou B. Curative effectiveness and safety of osimertinib in the treatment for non-small-cell lung cancer: a meta-analysis of the experimental evidence. Onco Targets Ther 2018; 11: 9033-9047.","DOI":"10.2147\/OTT.S182077"},{"key":"72512","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.2147\/OTT.S182077","DOI":"10.2147\/OTT.S182077"}],"container-title":["Acta Dermato-Venereologica"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/40555\/47494","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/download\/40555\/47494","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,28]],"date-time":"2024-08-28T07:43:23Z","timestamp":1724831003000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/actadv\/article\/view\/40555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,28]]},"references-count":55,"URL":"https:\/\/doi.org\/10.2340\/actadv.v104.40555","relation":{},"ISSN":["1651-2057","0001-5555"],"issn-type":[{"value":"1651-2057","type":"electronic"},{"value":"0001-5555","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,28]]}}}